33996-33-7
中文名稱
N-乙酰-L-4-羥基脯氨酸
英文名稱
Oxaceprol
CAS
33996-33-7
EINECS 編號
251-780-6
分子式
C7H11NO4
MDL 編號
MFCD00037339
分子量
173.17
MOL 文件
33996-33-7.mol
更新日期
2025/05/09 16:22:26
33996-33-7 結(jié)構(gòu)式
基本信息
中文別名
N-乙酰-L-4-羥基脯氨酸N-乙酰-L-羥脯氨酸
奧沙西羅
酰羥氫吡咯酸
1-乙酰基-4-羥基吡咯烷羧酸
4-羥基-N-乙?；彼?BR>反式-1-乙酰基-4-羥基-L-脯氨酸
N-乙酰-4-羥基-L-脯氨酸
N-乙酰-4-羥基脯氨酸
N-乙酰-L-羥基脯氨酸
英文別名
(2S,4R)-4-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID(4R,2S)-1-ACETYL-4-HYDROXY-PYRROLIDINE-2-CARBOXYLIC ACID
ACETYL-4-HYDROXY-L-PROLINE
ACETYL-L-4-HYDROXYPROLINE
AC-HYDROXYPROLINE
AC-HYP-OH
N-ACETYL-4-HYDROXY-L-PROLINE
N-ACETYLHYDROXY-L-PROLINE
N-ACETYL-L-HYDROXYPROLINE
N-AC-L-HYP
N-ALPHA-ACETYL-L-4-TRANS-HYDROXYPROLINE
N-ALPHA-ACETYL-L-HYROXYPROLINE
N-ALPHA-ACETYL-TRANS-4-HYROXY-L-PYROLLIDINE
OXACEPROL
TRANS-1-ACETYL-4-HYDROXY-L-PROLINE
trans-l-prolin
(R)-N-Acetyl-4-hydroxy-L-proline
N-Acetyl-4-hydroxyproline
N-Acetylhydroxyproline
N-Acetyl-trans-4-hydroxy-L-proline
所屬類別
生物化工：脯氨酸類衍生物物理化學性質(zhì)
熔點132-133 °C (dec.)(lit.)
比旋光度-119 º (c=4 in H2O)
沸點303.8°C (rough estimate)
密度1.3346 (rough estimate)
蒸氣壓0Pa at 20℃
折射率1.4490 (estimate)
儲存條件Store at RT.
溶解度DMSO : ≥ 32 mg/mL (184.79 mM)
酸度系數(shù)(pKa)3.48±0.40(Predicted)
形態(tài)結(jié)晶粉末
顏色白色
旋光性 (optical activity)[α]20/D 119°, c = 4 in H2O
Merck14,6903
BRN84043
InChIKeyBAPRUDZDYCKSOQ-RITPCOANSA-N
LogP-1.51 at 20℃
CAS 數(shù)據(jù)庫33996-33-7(CAS DataBase Reference)
EPA化學物質(zhì)信息L-Proline, 1-acetyl-4-hydroxy-, (4R)- (33996-33-7)
N-乙酰-L-4-羥基脯氨酸價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/05/22 | B23767 | N-乙酰-4-羥基脯氨酸, 99% N-Acetyl-trans-4-hydroxy-L-proline, 99% | 33996-33-7 | 2g | 445元 |
| 2025/05/22 | B23767 | N-乙酰-4-羥基脯氨酸, 99% N-Acetyl-trans-4-hydroxy-L-proline, 99% | 33996-33-7 | 10g | 1177元 |
| 2025/05/22 | HY-17490 | N-乙酰-L-4-羥基脯氨酸 Oxaceprol | 33996-33-7 | 1g | 100元 |
常見問題列表
生物活性
Oxaceprol (N-acetyl-L-hydroxyproline) 是一種抗炎性藥物，用于治療骨關(guān)節(jié)炎。體內(nèi)研究
Oxaceprol, at 6 mg/kg/day for 7 days, significantly reduces both the surface area and wet weight of cotton pellet granulomas, being slightly less effective than indomethacin, 3 mg/kg.
Oxaceprol (6–54 mg/kg/day) given therapeutically had no effect on the primary paw oedema response, but inhibits secondary lesions in the ears and tail.
Oxaceprol does not inhibit the synthesis of prostaglandins in vitro, but markedly inhibits neutrophil infiltration into the joints of rats with adjuvant arthritis.
| Animal Model: | Male Sprague-Dawley rats. |
| Dosage: | 18, 50 or 150 mg/kg. |
| Administration: | Gavage daily for 15 days. |
| Result: | Produced comparable inhibition of hyperalgesia to that produced by indomethacin. |